InspireMD (NSPR) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Polyrizon (PLRZ) has outperformed InspireMD (NSPR) over the past year, gaining 23.2% versus a loss of 78.8%. InspireMD is the larger company by market cap ($22.3 million vs $21.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSPR | PLRZ |
|---|---|---|
| Share price | $0.48 | $8.87 |
| Market cap | $22.31M | $21.54M |
| 1-day change | -6.61% | -3.06% |
| YTD return | -71.12% | +4.48% |
| 1-year return | -78.76% | +23.19% |
| 5-year return | -87.88% | — |
| EPS (TTM) | $-0.62 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $18.20 |
| 52-week low | $0.467 | $2.88 |
| Distance from 52-week high | -81.10% | -51.26% |
| Analyst consensus | none | — |
| Avg. price target upside | +593.75% | — |
| Average volume | 77.47K | 60.55K |
| Shares outstanding | 46.49M | 2.43M |
| Employees | 127 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed NSPR by 102.0 percentage points over the past year.
About InspireMD
NSPR stock →InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
Healthcare · Medical Devices · 127 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Healthcare · Biotechnology · 2 employees
NSPR vs PLRZ FAQ
Which is bigger, InspireMD or Polyrizon?
InspireMD (NSPR) is larger, with a market capitalization of $22.31M compared with $21.54M for Polyrizon (PLRZ).
Which stock has performed better over the past year, NSPR or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -78.76% for NSPR (price return, excluding dividends). Past performance does not predict future results.
Are InspireMD and Polyrizon in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for InspireMD and Biotechnology for Polyrizon.